← ANALYST RATINGS · TIPRANKS
Spruce Biosciences (SPRB): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy0 Hold0 Sell
Ratings of 5 analysts in the last 3 months12-month forecast
Based on 5 price targets given in the last 3 months, the average target is $155, the highest $230, the lowest $104. The average is +289.9% from the last price of $39.65.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $38.00 → $39.00+2.6% | Hold | −1.6% | Reiterated | 17.10.26on TipRanks 06:07 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $37.00 → $38.00+2.7% | Sell | −4.2% | Downgrade | 17.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $35.00 → $36.00+2.9% | Sell | −9.2% | Downgrade | 17.10.26on TipRanks 05:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $37.00 → $38.00+2.7% | Hold | −4.2% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $37.00 → $38.00+2.7% | Hold | −4.2% | Reiterated | 17.10.26on TipRanks 05:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $41.00 → $38.00−7.3% | Hold | −4.2% | Reiterated | 15.10.26on TipRanks 05:05 | — | |
| Albert Lowe★★★★★★★★★★#3118 · hits 41% · avg +8.2% | Craig-Hallum | $140 | Buy | +253.1% | Reiterated | 30.09.26on TipRanks 09:10 | +3.0%next day −8.0% · 5 days −10.5% | ↗ |
| Daniel Brims★★★★★★★★★★#12312 · hits 19% · avg −36.9% | Lake Street | $149 | Buy | +275.8% | Initiated | 17.09.26on TipRanks 07:55 | −1.7%next day −1.6% · 5 days −9.8% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $150 | Buy | +278.3% | Reiterated | 26.08.26on TipRanks 06:16 | −3.1%next day +2.3% · 5 days −2.8% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $230 | Buy | +480.1% | Reiterated | 25.08.26on TipRanks 07:50 | +7.8%next day −3.1% · 5 days −11.8% | ↗ |
| Debjit Chattopadhyay★★★★★★★★★★#506 · hits 48% · avg +17.0% | Guggenheim | $123 → $104−15.4% | Buy | +162.3% | Reiterated | 17.08.26on TipRanks 07:20 | +1.0%next day +0.5% · 5 days +12.0% | ↗ |
| Madison Elsaadi★★★★★★★★★★#984 · hits 54% · avg +35.6% | B. Riley Securities | $160 | Buy | +303.5% | Initiated | 13.07.26on TipRanks 08:21 | −2.6%next day −4.5% · 5 days −7.1% | ↗ |
| Catherine Novack★★★★★★★★★★#905 · hits 41% · avg +25.1% | JonesTrading | $135 | Buy | +240.5% | Initiated | 08.06.26on TipRanks 21:15 | −0.3%next day −2.3% · 5 days −5.7% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | $140 → $120−14.3% | Buy | +202.6% | Reiterated | 15.05.26on TipRanks 11:20 | −7.6%next day −4.3% · 5 days −5.9% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $170 → $150−11.8% | Buy | +278.3% | Reiterated | 14.05.26on TipRanks 06:00 | +1.7%next day −7.6% · 5 days −9.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Spruce Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $156 at a price of $48.58 (+220.1%); now: $155 at $39.65 (+289.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 9 | 8 | 7 |
| Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-5.68 (from $-7.00 to $-4.24). Last quarter: $-6.68.
Best top-analyst consensus in the sector · Healthcare
About Spruce Biosciences
- CEO: Javier Szwarcberg
- Employees: 22
- 611 Gateway Boulevard, South San Francisco, CA, 94080, US
- www.sprucebio.com
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Data from the stock’s TipRanks forecast page, read 114 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗